Mineralys Therapeutics (MLYS) Enterprise Value (2022 - 2026)

Mineralys Therapeutics has disclosed Enterprise Value across 5 years of filings, most recently posting -$644.9 million for Q1 2026.

• Enterprise Value for Q1 2026 came in at -$644.9 million, down 88.02% year-over-year; the trailing twelve-month figure through Mar 2026 was -$644.9 million (down 88.02% YoY), and the FY2025 annual result was -$655.6 million, down 230.8% from the prior year.
• Enterprise Value came in at -$644.9 million for Q1 2026 at Mineralys Therapeutics, up from -$655.6 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$107.2 million in Q4 2022 to a low of -$655.6 million in Q4 2025.
• The 5-year median for Enterprise Value is -$290.9 million (2023), against an average of -$342.5 million.
• Across the five-year window, Enterprise Value grew 16.22% in 2024 and slumped 230.8% in 2025, its largest moves.
• Mineralys Therapeutics' Enterprise Value stood at -$107.2 million in 2022, then slumped by 120.6% to -$236.6 million in 2023, then advanced by 16.22% to -$198.2 million in 2024, then plunged by 230.8% to -$655.6 million in 2025, then climbed by 1.63% to -$644.9 million in 2026.
• The last three Enterprise Value figures came in at -$644.9 million (Q1 2026), -$655.6 million (Q4 2025), and -$592.4 million (Q3 2025), per Business Quant data.